Mr. Michal Efraty reports

NEUROTHERA HIGHLIGHTS ENHANCEMENT OF U.S. PATENT PORTFOLIO THROUGH COLLABORATION WITH CLEARMIND COVERING LSD, KETAMINE AND IBOGAINE COMBINATIONS

Neurothera Labs Inc. today highlighted the expansion of the U.S. intellectual property portfolio through its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND).

As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (LSD), ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide (PEA), Neurothera's proprietary technology.

The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and posttraumatic stress disorder, as well as pain and substance use disorders.

These U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

The continued maturation of the patent portfolio reflects the broader potential applications of Neurothera's PEA technology when combined with psychoactive compounds such as psychedelic compounds. The company believes that these combinations may support the development of novel therapeutic approaches across multiple neuropsychiatric and substance use disorder indications.

Neurothera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental-health conditions. The companies remain focused on combining PEA with psychedelic-derived compounds, while enhancing the intellectual property portfolio supporting these innovative therapeutic programs

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.